Special booster dose for Covid 19 approved by the Food and Drug Administration. FDA has officially approved this special booster dose on Wednesday for people with high risk. This means this booster dose from Pfizer will be used to treat the people who have severe infections of Coronarivus and are at high risk.
What’s new about Pfizer’s Booster Shot?
FDA has released a statement regarding the authorization of Pfizer’s Booster Dose. According to the official information, these doses will be provided to citizens 65 years of age and those who have the job of exposing themselves to Covid-19 affected areas.
Since FDA is not the only authority for such certifications, the use of Pfizer’s special booster dose will not be available for public use until approval from the Critical Centers for Disease Control and Prevention Committee. The committee will first analyze the reports and feedback and then will finalize this booster for public use.
According to CDC’s director Dr. Rochelle Walensky, the new Pfizer booster shot will be made available for the public in a few days. He has stated this on Thursday, a day after the official authorization of the FDA to this booster shot. Hopefully, we will get to use this special Covid-19 booster shot for public use very soon as the committee has already started utilizing data and is all set to approve this booster shot.
FDA has been working on improving the effectiveness of the existing vaccines to cure patients with Covid-19 infection. Currently, there are two authorized vaccines present in the United States i.e. Pfizer and Moderna. They were performing different types of tests on people with low immune systems due to Covid 19 infection.
Now, after inventing the special booster shot, Pfizer approached to FDA and they have already authorized their special shot to cure patients with a low immune system due to the high risk of Covid-19 infection.
What’s surprising here is FDA has approved the use of Pfizer’s booster shot for the young generation. Yes, young people 18 years of age or above who are at high risk can use this special dose.
Many people are prone to get infected due to high-risk jobs. They are more exposed to Coronavirus than other people. If we talk about the jobs that are at high risk of Covid-19 infection, teachers, healthcare workers, grocery workers, prisoners, daycare staff, and all the other professions that need more intervention with unknown people.
The official Statement
“This pandemic is dynamic and evolving, with new data about vaccine safety and effectiveness becoming available every day,” Acting FDA Commissioner Janet Woodcock said in a statement announcing the authorization. “As we learn more about the safety and effectiveness of COVID-19 vaccines, including the use of a booster dose, we will continue to evaluate the rapidly changing science and keep the public informed.”
According to CDC’s official report, there are over 53 million Americans with the age group of 65 and above. The report also mentions the number of healthcare workers that are present in the United States. Around 20 million people are associated with the healthcare industry, which means they are working in high-risk areas.
Moreover, over 100 million people have been facing different types of healthcare issues. These 100 million people are at high risk of losing their lives if they ever get infected with Covid-19.
Who is excluded from using Pfizer’s Booster Shot?
According to FDA’s report and CDC’s analysis report, the only age group that is excluded from using the Pfizer’s Booster shot is 16 and 17 years kids. Pfizer has already applied for their special shot for use to the age group of 16 and 17 years. However, they are unable to show their data and feedback. The data lacks safety of the age below 18 for the third-shot of the vaccine.
Both BioNTech and Pfizer have applied for the legal license to use their special Booster Shot for the citizens of the United States. In their application, they have mentioned above giving this Booster Shot after six months of the second jab of the existing Covid-19 vaccine.
The recent meeting of the committee has opposed the broad use of this special booster shot as it lacks the required data. The members of the committee have asked others to point out the drawbacks of this shot. They might ask Pfizer to present more evidence to use this booster shot to the age group below 18. We will get to hear more about Pfizer’s special shot in the coming days.